Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in vitro

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in vitro. / Zhou, Yuyong; Gammeltoft, Karen A.; Galli, Andrea; Offersgaard, Anna; Fahnøe, Ulrik; Ramirez, Santseharay; Bukh, Jens; Gottwein, Judith M.

In: Viruses, Vol. 13, No. 10, 2082, 2021.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Zhou, Y, Gammeltoft, KA, Galli, A, Offersgaard, A, Fahnøe, U, Ramirez, S, Bukh, J & Gottwein, JM 2021, 'Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in vitro', Viruses, vol. 13, no. 10, 2082. https://doi.org/10.3390/v13102082

APA

Zhou, Y., Gammeltoft, K. A., Galli, A., Offersgaard, A., Fahnøe, U., Ramirez, S., Bukh, J., & Gottwein, J. M. (2021). Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in vitro. Viruses, 13(10), [2082]. https://doi.org/10.3390/v13102082

Vancouver

Zhou Y, Gammeltoft KA, Galli A, Offersgaard A, Fahnøe U, Ramirez S et al. Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in vitro. Viruses. 2021;13(10). 2082. https://doi.org/10.3390/v13102082

Author

Zhou, Yuyong ; Gammeltoft, Karen A. ; Galli, Andrea ; Offersgaard, Anna ; Fahnøe, Ulrik ; Ramirez, Santseharay ; Bukh, Jens ; Gottwein, Judith M. / Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in vitro. In: Viruses. 2021 ; Vol. 13, No. 10.

Bibtex

@article{5d58bc4a33414c53a6819a667dfff8fc,
title = "Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in vitro",
abstract = "We report the in vitro efficacy of ion-channel inhibitors amantadine, memantine and rimantadine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In VeroE6 cells, rimantadine was most potent followed by memantine and amantadine (50% effective concentrations: 36, 80 and 116 μM, respectively). Rimantadine also showed the highest selectivity index, followed by amantadine and memantine (17.3, 12.2 and 7.6, respectively). Similar results were observed in human hepatoma Huh7.5 and lung carcinoma A549-hACE2 cells. Inhibitors interacted in a similar antagonistic manner with remdesivir and had a similar barrier to viral escape. Rimantadine acted mainly at the viral post-entry level and partially at the viral entry level. Based on these results, rimantadine showed the most promise for treatment of SARS-CoV-2.",
keywords = "Adamantane, Antiviral, Barrier to escape, Combination treatment, COVID-19, Drug repurposing, Hepatitis C virus p7 inhibitor, Ion-channel inhibitor, Remdesivir, SARS-CoV-2",
author = "Yuyong Zhou and Gammeltoft, {Karen A.} and Andrea Galli and Anna Offersgaard and Ulrik Fahn{\o}e and Santseharay Ramirez and Jens Bukh and Gottwein, {Judith M.}",
note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
doi = "10.3390/v13102082",
language = "English",
volume = "13",
journal = "Viruses",
issn = "1999-4915",
publisher = "M D P I AG",
number = "10",

}

RIS

TY - JOUR

T1 - Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in vitro

AU - Zhou, Yuyong

AU - Gammeltoft, Karen A.

AU - Galli, Andrea

AU - Offersgaard, Anna

AU - Fahnøe, Ulrik

AU - Ramirez, Santseharay

AU - Bukh, Jens

AU - Gottwein, Judith M.

N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021

Y1 - 2021

N2 - We report the in vitro efficacy of ion-channel inhibitors amantadine, memantine and rimantadine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In VeroE6 cells, rimantadine was most potent followed by memantine and amantadine (50% effective concentrations: 36, 80 and 116 μM, respectively). Rimantadine also showed the highest selectivity index, followed by amantadine and memantine (17.3, 12.2 and 7.6, respectively). Similar results were observed in human hepatoma Huh7.5 and lung carcinoma A549-hACE2 cells. Inhibitors interacted in a similar antagonistic manner with remdesivir and had a similar barrier to viral escape. Rimantadine acted mainly at the viral post-entry level and partially at the viral entry level. Based on these results, rimantadine showed the most promise for treatment of SARS-CoV-2.

AB - We report the in vitro efficacy of ion-channel inhibitors amantadine, memantine and rimantadine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In VeroE6 cells, rimantadine was most potent followed by memantine and amantadine (50% effective concentrations: 36, 80 and 116 μM, respectively). Rimantadine also showed the highest selectivity index, followed by amantadine and memantine (17.3, 12.2 and 7.6, respectively). Similar results were observed in human hepatoma Huh7.5 and lung carcinoma A549-hACE2 cells. Inhibitors interacted in a similar antagonistic manner with remdesivir and had a similar barrier to viral escape. Rimantadine acted mainly at the viral post-entry level and partially at the viral entry level. Based on these results, rimantadine showed the most promise for treatment of SARS-CoV-2.

KW - Adamantane

KW - Antiviral

KW - Barrier to escape

KW - Combination treatment

KW - COVID-19

KW - Drug repurposing

KW - Hepatitis C virus p7 inhibitor

KW - Ion-channel inhibitor

KW - Remdesivir

KW - SARS-CoV-2

U2 - 10.3390/v13102082

DO - 10.3390/v13102082

M3 - Journal article

C2 - 34696509

AN - SCOPUS:85117348179

VL - 13

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 10

M1 - 2082

ER -

ID: 283131651